Drugs / IB-T101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06819293 | Dec 2024 → Dec 2027 expected | clear cell renal carcinoma | Grit Biotechnology | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IB-T101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06819293 ↗ |